Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Tianyin Receives SFDA Approval for Statin

publication date: Jul 31, 2008

Tianyin Pharmaceutical, Co. was given SFDA approval for a generic version of a statin drug, simvastatin tablets. Simvastatin was developed by Merck, which markets the drug as Zocor. The US patent for the drug expired in 2006. Simvastatin is used to control hypercholesterolemia and treat coronary heart diseases, the only statin approved by the SFDA for these conditions. Tianyin has the ability to produce $2 million of the drug annually. More details...

Stock Symbols: (OTCBB: TYNP) (NYSE: MRK)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital